---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-096799"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:02:58.032360+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Longeveron reports Q3 2024 revenue up 177% YoY to $1.8M; HLHS trial enrollment >80%

## Summary
- Revenue for nine months ended Sept 30, 2024: $1.8M, up 177% YoY from $0.6M.
- Net loss narrowed to $11.9M for nine months 2024 from $15.3M in 2023, a 23% improvement.
- Cash and equivalents $22.8M; expects to fund operations through Q4 2025.
- Phase 2b HLHS trial ELPIS II >80% enrolled; FDA confirmed pivotal trial acceptable for BLA if positive.
- Phase 2a Alzheimer's data (CLEAR MIND) presented at AAIC and CTAD24.

## SEC filing metadata
- accession: 0001213900-24-096799
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/0001213900-24-096799-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000121390024096799/ea0220665-8k_longe.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-096799
- JSON: https://secwatch.observer/filing/0001213900-24-096799.json
- Plain text: https://secwatch.observer/filing/0001213900-24-096799.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.